We are open seven days a week Monday through Friday from 8 a.m
stride length distance between the mid point of the fore paw and hind paw comparing left and right strides)
Track your goal If you truly need 20%plus weight loss or aggressive multisystem change (diabetes, MASLD, OSA, stacked CV risk), clinical data point toward starting the conversation with tirzepatide. If your goals are strong but more modest steady doubledigit loss and proven cardiovascular protection semaglutide remains a heavyweight with the longest outcome track record. 2
The glucagon component and unique considerations Because retatrutide is the first widely available triple agonist in the research peptide space, some of its effects do not have direct precedent from semaglutide or tirzepatide research
Note: Retatrutide is still in clinical trials and not FDA-approved to treat obesity or for weight loss
Our English-speaking clinicians coordinate every aspect of your care from initial evaluation to prescription support and follow-up
